Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347670 | 1.00 | CNR2 (0.39) | CNR2HDAC8HSD17B10GRIN2BGRIN2C | |
| SCHEMBL15130409 | 1.00 | CNR2 (0.39) | CNR2HDAC8HSD17B10GRIN2BGRIN2C | |
| SCHEMBL6466584 | 0.88 | HDAC8 (0.37) | CNR2HDAC8HSD17B10GRIN2BGRIN2C | |
| SCHEMBL30977317 | 0.88 | HDAC8 (0.37) | CNR2HDAC8HSD17B10GRIN2BGRIN2C | |
| SCHEMBL19389888 | 0.86 | HDAC8 (0.37) | HDAC8HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL1848946 | 0.86 | HSD17B10 (0.41) | HDAC8HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL13059379 | 0.86 | HDAC8 (0.37) | HDAC8HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL19484832 | 0.86 | HDAC8 (0.37) | HDAC8HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL193268 | 0.86 | HSD17B10 (0.41) | HDAC8HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL15116535 | 0.86 | HDAC8 (0.37) | HDAC8HSD17B10CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112956-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-2933247-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20170197983-A1 | HETEROCYCLIC COMPOUNDS HAVING CHOLESTEROL 24-HYDROXYLASE ACTIVITY | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9643957-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150315209-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2933247-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-10-21 | — | — | EP | disclosed |
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112956-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | CYP46A1, CYP27A1, NCEH1 | CNR2 858/4885HDAC8 355/4885HSD17B10 26/4885 |
| US-20170197983-A1 | HETEROCYCLIC COMPOUNDS HAVING CHOLESTEROL 24-HYDROXYLASE ACTIVITY | CYP46A1, CYP27A1, NCEH1 | CNR2 858/4885HDAC8 355/4885HSD17B10 26/4885 |
| US-20150315209-A1 | HETEROCYCLIC COMPOUND | HCN4, KCNH1, SCN4A | CNR2 320/4885HDAC8 108/4885HSD17B10 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.